Diadexus Inc: (OTC: DDXS)
$0.76
-0.04 (-4.43%)
Volume 73,287
May 22 02:26 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.73 - 0.80 |
| 52wk Low - High | 0.28 - 0.88 |
| Previous Close | 0.79 |
| Avg. Volume | 74,095 |
| Industry | MED PRODUCTS |
| Market Cap | 42.57 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.93 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.05 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
177 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.05 |
| Current Quarter Estimate | -0.02 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -0.05 |
| Expected Earnings Growth | NA |
Company Description
DiaDexus, Inc. operates as a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The Company's patented product PLAC Test for Lp-PLA2, identifies hidden risk for heart attack and stroke. The PLAC Test is the only blood test cleared by the FDA to assess risk for coronary heart disease and ischemic stroke associated with atherosclerosis. DiaDexus, Inc. is headquartered in San Francisco, California.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.02 | -0.02 | -0.05 | -0.03 |
| Number of Estimates | 1 | 1 | 2 | 2 |
| Low Estimate | -0.02 | -0.02 | -0.07 | -0.07 |
| High Estimate | -0.02 | -0.02 | -0.02 | NA |
| Year Ago EPS | -0.02 | 0.00 | -0.05 | -0.05 |
| EPS Growth | 0.00% | NA | 10.00% | 33.33% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| DIADEXUS INC | DDXS | 0.79 | |
|
| CONCEPTUS INC | CPTS | 30.98 | |
|
| ATRICURE INC | ATRC | 8.99 | |
|
| INVIVO THERAPT | NVIV | 2.90 | |
|
| TRANS1 INC | TSON | 1.59 | |
|
| ABAXIS INC | ABAX | 44.22 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 73.04 | |
|
| BIO-RAD LABS -A | BIO | 116.12 | |
|
| BIOLIFE SOL INC | BLFS | 0.38 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -0.05 |
| Sales | 21 |
| Net Income | -3 |
| Price/Earnings | NA |
| Price/Book | 4.76 |
| Price/Cash Flow | NA |
| Price/Sales | 1.99 |
News
diaDexus, Inc. Reports First Quarter 2013 Financial Results - Globenewswire
May 6, 2013
diaDexus Inc. to Present at the Taglich Brothers 10th Annual Small Cap Equity Conference - Globenewswire
Apr 18, 2013
diaDexus, Inc. to Host Conference Call and Webcast May 6, 2013 to Discuss First Quarter 2013 Financial Results - Globenewswire
Apr 17, 2013
Competing in the Global Molecular Diagnostics Market - 2013 - M2
Apr 11, 2013
2013 Pap Smear/HPV Testing Market: US, Europe, Japan - Test Volume and Sales Forecasts by Country - M2
Mar 28, 2013
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Suppliers - M2
Mar 28, 2013
2013 Analysis of the Global Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers - M2
Mar 27, 2013
Competing in the US Cancer Diagnostics Market: Over 50 Company Profiles Included - M2
Mar 25, 2013
Broker Recommendations
| Current ABR | NA |
| ABR (Last Week) | NA |
| # of recs in ABR | NA |
| Average Target Price | 0.85 |
| Industry Rank by ABR | 177 out of 265 |
| Rank in Industry | 5 out of 73 |
